Trials / Completed
CompletedNCT04023812
Stage III NSCLC RWE in Chinese Patients
Real-World Molecular Testing, Treatment Patterns and Clinical Outcomes in Chinese Patients With Stage III NSCLC- A Prospective, Non-Interventional Study(MOOREA)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are to assess molecular testing, treatment patterns and associated clinical outcomes in Chinese patients with treatment-naïve stage III non-small cell lung cancer (NSCLC) in real world setting. This study is a prospective, non-interventional study. It is descriptive in nature and does not attempt to test any specific a priori hypotheses.
Conditions
Timeline
- Start date
- 2019-07-16
- Primary completion
- 2024-02-29
- Completion
- 2024-02-29
- First posted
- 2019-07-18
- Last updated
- 2025-02-18
Locations
25 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04023812. Inclusion in this directory is not an endorsement.